Navigation Links
Chimerix to Present at Two Upcoming Investor Conferences
Date:11/12/2009

RESEARCH TRIANGLE PARK, N.C., Nov. 12 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company advancing orally-available antiviral therapeutics to address life-threatening diseases, announced today that Kenneth I. Moch, Chief Operating Officer, will present a corporate overview at two upcoming investor conferences. Mr. Moch will discuss the company's technology assets and pipeline, including CMX001, a broad-spectrum antiviral being developed for the treatment of BK virus and cytomegalovirus in immunocompromised transplant patients and as a biodefense countermeasure in the event of a smallpox release.

Mr. Moch will speak at the Lazard Capital Markets 6th Annual Healthcare Conference on Wednesday, November 18, 2009 at 9:30 a.m. ET and at the Piper Jaffray 21st Annual Health Care Conference on Tuesday, December 1, 2009 at 9:50 a.m. ET. Both meetings are being held in New York City.

About Chimerix

Chimerix, Inc., is developing antiviral therapeutics to treat life-threatening diseases. Led by a world-class antiviral drug development team, Chimerix is advancing programs to address cytomegalovirus (CMV), BK virus, smallpox, human immunodeficiency virus (HIV), hepatitis C virus (HCV), respiratory syncytial virus (RSV) and influenza. The company's lead compound, CMX001, is currently in Phase 1 and 2 clinical studies for the treatment of BK virus and CMV, potentially deadly infections among immunocompromised patients. CMX001 is also being evaluated for use as a biodefense countermeasure in the event of a smallpox release. Chimerix has received financing from leading venture capital firms, including Canaan Partners, Alta Partners, Sanderling Ventures, Frazier Healthcare Ventures and Asset Management Company, in addition to U.S. Government grants. Additional information about Chimerix and its antiviral drug development programs may be found online at http://www.chimerix-inc.com.

SOURCE Chimerix, Inc.


'/>"/>
SOURCE Chimerix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox
2. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
3. Tobira Therapeutics Announces Presentation of TBR-652 Data at European AIDS Conference
4. Trubion Announces Acceptance of Two Presentations on Its TRU-016 Product Candidate at the 2009 ASH Annual Meeting
5. Onyx Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
6. Webcast Alert: Isis Pharmaceuticals and Genzyme Corporation to Present Mipomersen Phase 3 Data in HoFH During AHA
7. Hologic to Present at NASDAQ OMX 23rd Investor Program in London
8. Accera, Inc. To Present at Lazard Capital Markets 6th Annual Healthcare Conference
9. Abaxis, Inc. to Present at the Sidoti & Company Second Annual New York Institutional Investor Forum
10. CryoLife to Present at Upcoming Investor Conferences in New York
11. Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... India , January 16, 2017 ... Market Research, titled, "Sterilization Technologies Market by Type and ... the global sterilization technologies market is expected to reach ... growing at a CAGR of 5.8% from 2016 to ... market in 2015, with more than half share, in ...
(Date:1/16/2017)...   Linde Gas North America LLC  today announced ... business of The Service Center LLC, a market leading provider ... providers in the Midwest and Southeast regions of the U.S. ... , The Service Center also has facilities in ... . Its primary services include: ...
(Date:1/16/2017)... FRANCISCO, Calif. , Jan. 16, 2017  Rigel ... on January 3, 2017 and January 16, 2017 the ... grant of inducement stock options to purchase an aggregate ... employees. These awards were granted pursuant to the Rigel ... material to the new employees entering into employment with ...
Breaking Medicine Technology:
(Date:1/16/2017)... MO (PRWEB) , ... January 16, 2017 , ... St. Louisans are well-aware of the ... , This year’s influenza shot seems to be having no effect on keeping ... at least half of the people around are coughing, sneezing, or sniffling ...
(Date:1/16/2017)... ... 16, 2017 , ... Board-certified oculoplastic surgeon Dr. Mehryar (Ray) ... journal of The American Society for Aesthetic Plastic Surgery, in which he details ... to correct drooping, retracted lower eyelids, which usually result from genetics, injury, thyroid ...
(Date:1/16/2017)... ... , ... One thing common to all types of cancer is that it’s ... The money spent screening for and treating cancer in the United States is estimated ... more than in any other country that has an advanced healthcare system, sometimes spending ...
(Date:1/16/2017)... ... January 16, 2017 , ... ... Chief Executive Officer of the medical device company, effective immediately. , “This is ... “Kevin has a strong track record in medical device market development and ...
(Date:1/15/2017)... ... January 15, 2017 , ... In this role, Courtney will be responsible ... the asthma & allergy friendly mark. This certification program was created by ASL and ... products to be more suitable for the 60+ million people living in the U.S. ...
Breaking Medicine News(10 mins):